FORMULATION DEVELOPMENT AND OPTIMIZATION OF ZOLMITRIPTAN TABLETS BY DIRECT COMPRESSION METHOD

The aim of the present study is to develop a robust formulation of Zolmitriptan Anti Migraine Analgesic drug as a Sustained release Matrix Tablets by direct compression method. The polymers like Karayagum, Guargum, and HPMC K100M and were used as sustained release polymer to retard the drug release. The tablets prepared were evaluated for various parameters like various density parameters, thickness, hardness, friability, disintegration time, wetting time and In-vitro dissolution time. All the parameters were found to be within limits. The invitro release pattern of final formulation was compared with the innovator. Zolmitriptan sustained-release formulation provides continual drug delivery over 12hours and reduces fluctuations in serum drug concentrations. This delayed release minimizes side effects related to high serum levels that occur with immediate-release formulations. It is effective, safe, and relatively well tolerated. An sustained release model drug tablet can lead to the reduction of the number of doses administered, leading to better patient compliance and less chances of overdose, in addition to which it can reduce the cost associated with treating pain symptoms.